Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomas
Valeria Barresi,
Serenella Cerasoli,
Giovanni Tuccari,
Corresponding Author
Valeria Barresi
Department of Human Pathology, University of Messina, Messina, and
Valeria Barresi, MD, Department Human Pathology, Policlinico Universitario G. Martino, Pad D, Via Consolare Valeria, 98125 Messina, Italy. Email: [email protected]Search for more papers by this authorSerenella Cerasoli
Unit of Anatomic Pathology, M. Bufalini Hospital, Cesena, Italy
Search for more papers by this authorGiovanni Tuccari
Department of Human Pathology, University of Messina, Messina, and
Search for more papers by this authorValeria Barresi,
Serenella Cerasoli,
Giovanni Tuccari,
Corresponding Author
Valeria Barresi
Department of Human Pathology, University of Messina, Messina, and
Valeria Barresi, MD, Department Human Pathology, Policlinico Universitario G. Martino, Pad D, Via Consolare Valeria, 98125 Messina, Italy. Email: [email protected]Search for more papers by this authorSerenella Cerasoli
Unit of Anatomic Pathology, M. Bufalini Hospital, Cesena, Italy
Search for more papers by this authorGiovanni Tuccari
Department of Human Pathology, University of Messina, Messina, and
Search for more papers by this authorAbstract
Since it has recently been reported that caveolin-1 (cav-1) may favor the progression of prostatic and renal cancers by stimulating tumor neoangiogenesis, we thought it of interest to analyze the correlation between cav-1 expression and tumor microvessel density (MVD) in meningiomas. In the present study we quantified cav-1 expression by immunohistochemistry and used CD105 immunohistochemical staining to measure MVD. Sixty-two formalin-fixed, paraffin-embedded, surgically resected meningiomas were submitted to the analysis. On the basis of cav-1 immuno-expression, cases were subdivided into meningiomas displaying a low (n = 34) and a high (n = 28) cav-1 immuno-expression, respectively. Mann–Whitney test showed that a significantly higher MVD was present in the cases with a high cav-1 expression than in those with a low expression (mean 24.44 vs. 41.28 microvessels/mm2) (P = 0.0001). Moreover, Spearman test revealed a significant positive correlation between cav-1 rate of expression and MVD counts in the meningiomas of our series (r = 0.390; P = 0.0023). Therefore, our study demonstrates the existence of an association between cav-1 expression and neoangiogenesis in meningiomas, suggesting that cav-1 may mediate the progression of these tumors by stimulating the angiogenic process. Besides, it is known that the progression of meningiomas is paralleled by an increase in MVD. The clarification of cav-1 role in the neoangiogensis of meningiomas may open new insights about the possibility of novel therapeutic strategies in these neoplasias.
REFERENCES
- 1 Anderson RG, Kamen BA, Tothberg KG, Lacey SW. Potocytosis: sequestration and transport of small molecules by caveolae. Science 1992; 255: 410–411.
- 2 Anderson RG. Caveolae: where incoming and outcoming messengers meet. Proc Natl Acad Sci USA 1993; 90: 10909–10913.
- 3 Yang G, Addai J, Wheeler TM et al. Correlative evidence that prostate cancer cell-derived caveolins-1 mediates angiogenesis. Hum Pathol 2007; 38: 1688–1695.
- 4 Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ. Increased expression of caveolins-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. J Urol 2004; 172: 718–722.
- 5 Kato K, Hida Y, Miyamoto M et al. Overexpression of caveolins-1 in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002; 94: 929–933.
- 6 Yoo SH, Park YS, Kim HR et al. Expression of caveolins-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003; 42: 195–202.
- 7 Barresi V, Cerasoli S, Paioli G et al. Caveolin-1 in meningiomas: expression and clinico-pathological correlations. Acta Neuropathol 2006; 112: 617–626.
- 8 Barresi V, Cerasoli SV, Itarelli E, Tuccari G. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol 2007; 114: 147–156.
- 9 Ding S, Li C, Lin S et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol 2006; 37: 861–866.
- 10 Dallago CM, Oliveira MC, Barbosa-Coutinho LM, Ferreira NP. Angiogenesis in craniopharyngiomas: microvascular density and tissue expression of the vascular endothelial growth factor (VEGF) and endostatin. Endocr Pathol 2005; 16: 355–362.
- 11 Lewy-Trenda I, Omulecka A, Janczukowicz J, Papierz W. The morphological analysis of vasculature and angiogenic potential in meningiomas: immunoexpression of CD31 and VEGF antibodies. Folia Neuropathol 2003; 41: 149–153.
- 12 Pistolesi S, Boldrini L, Gisfredi S et al. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol 2004; 30: 118–125.
- 13 Shono T, Inamura T, Torisu M, Suzuki SO, Fukui M. Vascular endothelial growth factor and malignant transformation of a meningioma: a case report. Neurol Res 2000; 22: 189–193.
- 14 Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergun S, Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 2000; 46: 938–947.
- 15 Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol 2004; 70: 183–202.
- 16 Louis ND, Scheithauer BW, Budka H, Von Deimling A, Kepes JJ. Meningiomas. In: P Kleihues, WK Cavenee, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000; 176–184.
- 17 Gougos A, St Jacques S, Greaves A et al. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 1992; 4: 83–92.
- 18 Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljunberg B, Rasmuson T. Endoglin (CD105) expression in human renal cell carcinoma. BJU Int 2006; 97: 706–710.
- 19 Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8.
- 20
Perry A,
Stafford SL,
Scheithauer BW,
Suman VJ,
Lohse CM.
The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas.
Cancer
1998; 82: 2262–2269.
10.1002/(SICI)1097-0142(19980601)82:11<2262::AID-CNCR23>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 21 Bender FC, Reymond MA, Bron C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 2000; 60: 5870–5878.
- 22 Park SS, Kim JE, Kim YA, Kim YC, Kim SW. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology 2005; 47: 625–630.
- 23 Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 2005; 103: 1186–1194.
- 24 Fang K, Fu W, Beardsley AR, Sun X, Lisanti MP, Liu J. Overexpression of caveolin-1 inhibits endothelial cell proliferation by arresting the cell cycle at G0/G1 phase. Cell Cycle 2007; 6: 199–204.
- 25 Galvagni F, Anselmi F, Salameh A, Orlandini M, Rocchigiani M, Oliviero S. Vascular endothelial growth factor receptor-3 activity is modulated by its association with caveolin-1 on endothelial membrane. Biochemistry 2007; 46: 3998–4005.
- 26 Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Beliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell 2003; 14: 334–347.
- 27 Pan YM, Yao YZ, Zhu ZH, Sun XT, Qiu YD, Ding YT. Caveolin-1 is important for nitric oxide-mediated angiogenesis in fibrin gels with human umbilical vein endothelial cells. Acta Pharmacol Sin 2006; 27: 1567–1574.
- 28 Shi L, Chen XM, Wang L, Zhang L, Chen Z. Expression of caveolin-1 in mucoepidermoid carcinoma of the salivary glands: correlation with vascular endothelial growth factor, microvessel density and clinical outcome. Cancer 2007; 109: 1523–1531.
- 29 Cheifetz S, Bellon T, Cales C et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992; 267: 19027–19030.
- 30 Burrows FJ, Derbyshire EJ, Tazzari PL et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumours: implications for diagnosis and therapy. Clin Cancer Res 1995; 1: 1623–1634.
- 31
Miller DW,
Graulich W,
Karges B et al.
Elevated expression of endoglin, a component of the TGF-β receptor complex, correlates with proliferation of tumour endothelial cells.
Int J Cancer
1999; 81: 568–572.
10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.0.CO;2-X CAS PubMed Web of Science® Google Scholar
- 32 Wang JM, Kumar S, Pye D, Van Aghtoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 1993; 54: 363–370.
- 33 Behrem S, Zrkovic K, Eskina N, Jonjic N. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma. Croat Med J 2005; 46: 417–422.
- 34 Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res 1998; 18: 1485–1500.
- 35 Fonsatti E, Altomonte M, Arslan P, Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets 2003; 3: 427–432.
- 36 Yao Y, Kubota T, Takeuchi H, Sato K. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 2005; 25: 201–206.
- 37 Massimino ML, Griffoni C, Spisni E, Toni M, Tomasi V. Involvement of caveolae and caveolae-like domains in signaling, cell survival and angiogenesis. Cell Signal 2002; 14: 93–98.
- 38 Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolin, caveolae and endothelial cell finctions. Arterioscler Thromb Vasc Biol 2003; 23: 1161–1168.
- 39 Lee H, Woodman SE, Engelman JA et al. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (Tyr14). J Biol Chem 2001; 276: 35150–35158.
- 40 Li S, Seitz R, Lisanti MP. Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. J Biol Chem 1996; 271: 3863–3868.
- 41 Simoncini M, Sattler M, Ishitsuka K et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 2004; 64: 7500–7506.
Citing Literature
